{ "design_conflicts": [ { "conflict_id": "NOVA4-CONFLICT-001", "constructive_resolution": "Preserve the intent but replace the score with prespecified placebo and active-comparator endpoints, confidence bounds, and a fit-for-purpose context of use.", "severity": "CRITICAL", "source_ids": [ "NOVA4_WHITEPAPER_CURRENT", "FDA_ACUTE_PAIN_2026", "FDA_PFDD_COA_2025", "FDA_ABUSE_POTENTIAL" ], "statement": "The legacy 10/10 analgesia and 10/10 euphoria scores are projected ordinal labels without a validated scale, comparator rule, uncertainty, or raw observations.", "status": "RESOLVED_BY_SPECIFICATION" }, { "conflict_id": "NOVA4-CONFLICT-002", "constructive_resolution": "Keep C2 peripheral and assign only measured peripheral analgesic/interaction effects, or redesign distribution and accept a new CNS and abuse-risk program. No central subjective credit is allowed before that decision and direct evidence.", "severity": "CRITICAL", "source_ids": [ "NOVA4_WHITEPAPER_CURRENT", "PUBMED_23822179", "PUBMED_32077093" ], "statement": "C2 is explicitly peripherally restricted while the euphoria table credits it with central anandamide bliss.", "status": "BLOCKED_DESIGN_DECISION" }, { "conflict_id": "NOVA4-CONFLICT-003", "constructive_resolution": "Measure C3 distribution and demonstrate a factorial subjective contribution across contexts; otherwise retain C3 only for measured peripheral or systemic effects.", "severity": "CRITICAL", "source_ids": [ "NOVA4_WHITEPAPER_CURRENT", "PUBMED_29486321" ], "statement": "C3 is described as peripheral yet is assigned deterministic central warmth and bonding.", "status": "BLOCKED_DIRECT_EVIDENCE" }, { "conflict_id": "NOVA4-CONFLICT-004", "constructive_resolution": "Require the positive-affect features and the abuse-potential constraint to pass independently; neither result may substitute for the other.", "severity": "CRITICAL", "source_ids": [ "NOVA4_WHITEPAPER_CURRENT", "FDA_ABUSE_POTENTIAL" ], "statement": "Strong euphoria and low abuse liability are asserted as simultaneously guaranteed even though euphoria is an abuse-related signal.", "status": "RESOLVED_BY_SPECIFICATION" }, { "conflict_id": "NOVA4-CONFLICT-005", "constructive_resolution": "Replace transferred multipliers with prespecified concentration-response matrices, an additivity model, uncertainty, and replication for the exact selected entities.", "severity": "MAJOR", "source_ids": [ "NOVA4_WHITEPAPER_CURRENT" ], "statement": "Fixed 3-6x and 1.5-2x literature multipliers are transferred to untested compounds and a three-way combination.", "status": "BLOCKED_DIRECT_EVIDENCE" }, { "conflict_id": "NOVA4-CONFLICT-006", "constructive_resolution": "Insert component pharmacology, exposure, combination, and phenotype evidence objects between synthesized identity and any subjective certificate.", "severity": "CRITICAL", "source_ids": [ "NOVA4_WHITEPAPER_CURRENT", "FDA_PFDD_COA_2025" ], "statement": "The synthesis target registry contains molecular graphs but the whitepaper treats those graphs as if they construct a human feeling.", "status": "RESOLVED_BY_SPECIFICATION" }, { "conflict_id": "NOVA4-CONFLICT-007", "constructive_resolution": "Evaluate the 24 exact novel triplets through staged component and combination gates, then select one by a signed, replayable decision object.", "severity": "CRITICAL", "source_ids": [ "NOVA4_WHITEPAPER_CURRENT" ], "statement": "No exact final C1/C2/C3 composition has been selected.", "status": "BLOCKED_DESIGN_DECISION" }, { "conflict_id": "NOVA4-CONFLICT-008", "constructive_resolution": "Define affiliative warmth as a measured context-of-use endpoint and explicitly test adverse or maladaptive social salience.", "severity": "MAJOR", "source_ids": [ "NOVA4_WHITEPAPER_CURRENT", "PUBMED_29486321", "FDA_PFDD_COA_2025" ], "statement": "Oxytocin signaling is treated as a universal bonding switch despite context-dependent human reward-learning effects.", "status": "BLOCKED_DIRECT_EVIDENCE" }, { "conflict_id": "NOVA4-CONFLICT-009", "constructive_resolution": "Permit only a domain-limited safety certificate constructed from authenticated empirical bounds and a strict positive margin.", "severity": "CRITICAL", "source_ids": [ "NOVA4_WHITEPAPER_CURRENT", "FDA_ICH_S7A" ], "statement": "Target saturation is treated as proof that arbitrary additional doses cannot cause lethal off-target, metabolite, interaction, or organ toxicity.", "status": "BLOCKED_DIRECT_EVIDENCE" } ], "features": [ { "acceptance_logic": "pain_primary_endpoint_pass AND placebo_superiority_pass AND active_comparator_comparison_pass AND rescue_use_supports_effect", "component_contributors": [ "C1", "C2", "C3", "COMBINATION" ], "feature_class": "DESIRED_OUTPUT", "feature_id": "NOVA4-FEAT-001", "legacy_target": "Opioid-level analgesia described as 10/10", "name": "Comparator-level analgesia", "operational_definition": "Direct patient-rated pain-intensity improvement with superiority to placebo and a prespecified, interpretable comparison against an active analgesic comparator, including rescue-medication use and duration.", "prohibited_inference": "Descriptor scores, target labels, animal nociception, or an unvalidated 10-point projection cannot establish clinical analgesia.", "required_evidence": [ "human_target_engagement", "validated_pain_intensity_endpoint", "active_and_placebo_comparators", "rescue_medication_accounting", "replicated_clinical_effect" ], "source_ids": [ "NOVA4_WHITEPAPER_CURRENT", "FDA_ACUTE_PAIN_2026", "FDA_PFDD_COA_2025", "PUBMED_34046921" ], "status": "BLOCKED_NO_DIRECT_EVIDENCE" }, { "acceptance_logic": "positive_affect_endpoint_pass AND timecourse_reproduced AND pharmacokinetic_alignment_pass AND NOVA4_FEAT_009_pass", "component_contributors": [ "C1", "C2", "C3", "COMBINATION" ], "feature_class": "DESIRED_OUTPUT", "feature_id": "NOVA4-FEAT-002", "legacy_target": "C1 opioid warm glow, projected 8-9/10 with synergy", "name": "Opioid-like warm positive affect", "operational_definition": "A reproducible warm positive-affect signal with characterized onset, peak, duration, dose-response, active comparator relationship, and simultaneous abuse-potential interpretation.", "prohibited_inference": "Enkephalin elevation, MOR pathway plausibility, or a euphoria score assigned in software cannot establish a felt warm glow.", "required_evidence": [ "fit_for_purpose_positive_affect_measure", "drug_liking_and_high_timecourse", "active_placebo_comparison", "pharmacokinetic_alignment", "abuse_potential_assessment" ], "source_ids": [ "NOVA4_WHITEPAPER_CURRENT", "FDA_ABUSE_POTENTIAL", "FDA_PFDD_COA_2025" ], "status": "BLOCKED_NO_DIRECT_EVIDENCE" }, { "acceptance_logic": "contentment_endpoint_pass AND sedation_discrimination_pass AND C2_factorial_contribution_pass AND NOVA4_FEAT_009_pass", "component_contributors": [ "C2", "COMBINATION" ], "feature_class": "DESIRED_OUTPUT", "feature_id": "NOVA4-FEAT-003", "legacy_target": "C2 anandamide bliss, projected +1/10", "name": "Relaxed contentment", "operational_definition": "A positive relaxation and contentment signal distinguishable from sleepiness, intoxication, cognitive impairment, and expectancy, with component attribution demonstrated in a factorial comparison.", "prohibited_inference": "A peripherally restricted FAAH inhibitor cannot be credited with a central subjective state without direct distribution and contribution evidence.", "required_evidence": [ "fit_for_purpose_relaxation_contentment_measure", "sedation_discrimination", "factorial_component_attribution", "measured_C2_distribution", "abuse_potential_assessment" ], "source_ids": [ "NOVA4_WHITEPAPER_CURRENT", "FDA_ABUSE_POTENTIAL", "PUBMED_23822179", "PUBMED_32077093" ], "status": "BLOCKED_NO_DIRECT_EVIDENCE" }, { "acceptance_logic": "affiliative_warmth_endpoint_pass AND context_consistency_pass AND adverse_social_effect_gate_pass AND C3_factorial_contribution_pass", "component_contributors": [ "C3", "COMBINATION" ], "feature_class": "DESIRED_OUTPUT", "feature_id": "NOVA4-FEAT-004", "legacy_target": "C3 warmth/bonding euphoria, projected +1-2/10", "name": "Affiliative warmth and comfort", "operational_definition": "A reproducible patient-reported warmth and social-comfort effect across prespecified contexts, without maladaptive trust, aggression, envy, impaired feedback learning, or other adverse social salience.", "prohibited_inference": "OTR agonism or oxytocin precedent cannot be translated into deterministic trust, bonding, or comfort for a different molecular graph.", "required_evidence": [ "fit_for_purpose_warmth_affiliation_measure", "context_stratified_social_assessment", "C3_factorial_component_attribution", "measured_C3_distribution", "adverse_social_effect_assessment" ], "source_ids": [ "NOVA4_WHITEPAPER_CURRENT", "FDA_PFDD_COA_2025", "PUBMED_29486321" ], "status": "BLOCKED_NO_DIRECT_EVIDENCE" }, { "acceptance_logic": "sleepy_awake_margin_pass AND vigilance_margin_pass AND overlap_with_positive_affect_confirmed", "component_contributors": [ "C1", "C2", "C3", "COMBINATION" ], "feature_class": "DESIRED_OUTPUT", "feature_id": "NOVA4-FEAT-005", "legacy_target": "Fully conscious, non-sedating euphoria", "name": "Full alertness", "operational_definition": "Wakefulness and vigilance remain within prespecified placebo-referenced margins throughout the period of positive subjective effect and analgesia.", "prohibited_inference": "Activity-dependent endogenous signaling does not by itself prove preserved alertness after systemic enzyme inhibition.", "required_evidence": [ "sleepy_awake_subjective_measure", "validated_vigilance_performance", "time_aligned_subjective_PK_data", "active_placebo_comparison" ], "source_ids": [ "NOVA4_WHITEPAPER_CURRENT", "FDA_ABUSE_POTENTIAL", "FDA_ICH_S7A" ], "status": "BLOCKED_NO_DIRECT_EVIDENCE" }, { "acceptance_logic": "memory_margin_pass AND attention_margin_pass AND executive_margin_pass AND reaction_time_margin_pass AND coordination_margin_pass", "component_contributors": [ "C1", "C2", "C3", "COMBINATION" ], "feature_class": "DESIRED_OUTPUT", "feature_id": "NOVA4-FEAT-006", "legacy_target": "Full cognitive clarity and sensory awareness", "name": "Cognitive clarity", "operational_definition": "Memory, attention, perception, executive function, reaction time, coordination, and postural performance remain within prospectively justified margins.", "prohibited_inference": "Absence of a sedative structural alert or a subjective report of wakefulness cannot establish unimpaired cognition.", "required_evidence": [ "validated_cognitive_battery", "psychomotor_performance", "baseline_and_placebo_comparison", "dose_and_timecourse_analysis" ], "source_ids": [ "NOVA4_WHITEPAPER_CURRENT", "FDA_ABUSE_POTENTIAL", "FDA_ICH_S7A" ], "status": "BLOCKED_NO_DIRECT_EVIDENCE" }, { "acceptance_logic": "sedation_margin_pass AND somnolence_AE_gate_pass AND motor_coordination_margin_pass", "component_contributors": [ "C1", "C2", "C3", "COMBINATION" ], "feature_class": "SAFETY_CONSTRAINT", "feature_id": "NOVA4-FEAT-007", "legacy_target": "Zero sedation", "name": "Non-sedating profile", "operational_definition": "No clinically meaningful somnolence, sedation, motor slowing, coordination loss, or inability to complete assessments across the tested exposure range.", "prohibited_inference": "A zero-sedation claim is prohibited outside the measured population, exposure range, and confidence bounds.", "required_evidence": [ "sedation_VAS", "adverse_event_analysis", "motor_activity_and_coordination", "exposure_response_analysis" ], "source_ids": [ "NOVA4_WHITEPAPER_CURRENT", "FDA_ABUSE_POTENTIAL", "FDA_ICH_S7A" ], "status": "BLOCKED_NO_DIRECT_EVIDENCE" }, { "acceptance_logic": "respiratory_rate_margin_pass AND tidal_volume_margin_pass AND oxygenation_margin_pass AND interaction_gate_pass", "component_contributors": [ "C1", "C2", "C3", "COMBINATION" ], "feature_class": "SAFETY_CONSTRAINT", "feature_id": "NOVA4-FEAT-008", "legacy_target": "No respiratory depression and active anti-OIRD protection", "name": "Respiratory preservation", "operational_definition": "Respiratory rate, tidal volume, oxygen saturation, blood gases where appropriate, and ventilatory response remain within prespecified margins under intended exposure and justified interaction conditions.", "prohibited_inference": "Finite endogenous production, receptor distribution, or rodent rescue precedent cannot prove zero human respiratory risk.", "required_evidence": [ "quantified_respiratory_core_battery", "exposure_response", "interaction_testing", "metabolite_assessment", "independent_replication" ], "source_ids": [ "NOVA4_WHITEPAPER_CURRENT", "FDA_ICH_S7A" ], "status": "BLOCKED_NO_DIRECT_EVIDENCE" }, { "acceptance_logic": "nonclinical_abuse_gate_pass AND clinical_abuse_signal_gate_pass AND reinforcement_boundary_pass", "component_contributors": [ "C1", "C2", "C3", "COMBINATION" ], "feature_class": "SAFETY_CONSTRAINT", "feature_id": "NOVA4-FEAT-009", "legacy_target": "Low or zero addiction despite strong euphoria", "name": "Acceptable abuse potential", "operational_definition": "Reward, reinforcement, drug liking, high, take-drug-again response, self-administration, diversion signals, and abuse-related adverse events satisfy a prespecified benefit-risk boundary.", "prohibited_inference": "Euphoria is itself an abuse-related signal and cannot be declared non-addictive from mechanism or lack of one animal self-administration result.", "required_evidence": [ "receptor_and_off_target_abuse_screen", "animal_behavioral_pharmacology", "human_abuse_potential_assessment_if_indicated", "drug_liking_high_take_again_measures", "clinical_abuse_AE_analysis" ], "source_ids": [ "NOVA4_WHITEPAPER_CURRENT", "FDA_ABUSE_POTENTIAL" ], "status": "BLOCKED_NO_DIRECT_EVIDENCE" }, { "acceptance_logic": "tolerance_gate_pass AND withdrawal_gate_pass AND impaired_control_gate_pass", "component_contributors": [ "C1", "C2", "C3", "COMBINATION" ], "feature_class": "SAFETY_CONSTRAINT", "feature_id": "NOVA4-FEAT-010", "legacy_target": "No physical or psychological dependence or withdrawal", "name": "No clinically significant dependence", "operational_definition": "Repeated exposure and discontinuation do not produce clinically significant tolerance, withdrawal, impaired control, or negative-reinforcement maintenance within the studied domain.", "prohibited_inference": "Tonic signaling, endogenous ligands, or an anti-craving precedent cannot establish absence of dependence for a new combination.", "required_evidence": [ "repeat_exposure_assessment", "tolerance_analysis", "withdrawal_assessment", "psychological_dependence_assessment", "longitudinal_follow_up" ], "source_ids": [ "NOVA4_WHITEPAPER_CURRENT", "FDA_ABUSE_POTENTIAL" ], "status": "BLOCKED_NO_DIRECT_EVIDENCE" }, { "acceptance_logic": "CNS_gate_pass AND cardiovascular_gate_pass AND respiratory_gate_pass AND organ_toxicology_gate_pass AND interaction_safety_pass", "component_contributors": [ "C1", "C2", "C3", "COMBINATION" ], "feature_class": "SAFETY_CONSTRAINT", "feature_id": "NOVA4-FEAT-011", "legacy_target": "No material CNS, cardiovascular, respiratory, or systemic toxicity", "name": "Vital-system and systemic safety", "operational_definition": "Central nervous, cardiovascular, respiratory, autonomic, hepatic, renal, immune, endocrine, reproductive, genotoxic, and interaction risks are characterized with adequate exposure margins.", "prohibited_inference": "Target saturation does not cap free-drug, metabolite, off-target, or organ toxicity.", "required_evidence": [ "safety_pharmacology_core_battery", "repeat_dose_toxicology", "off_target_and_covalent_profiling", "metabolite_safety", "combination_interaction_safety" ], "source_ids": [ "NOVA4_WHITEPAPER_CURRENT", "FDA_ICH_S7A" ], "status": "BLOCKED_NO_DIRECT_EVIDENCE" }, { "acceptance_logic": "all_empirical_bounds_authenticated AND strict_margin_positive AND intended_domain_explicit AND extrapolation_prohibited", "component_contributors": [ "C1", "C2", "C3", "COMBINATION" ], "feature_class": "SAFETY_CONSTRAINT", "feature_id": "NOVA4-FEAT-012", "legacy_target": "Structural impossibility of lethal overdose at any dose", "name": "Exposure-bounded overdose safety", "operational_definition": "A domain-limited safety certificate defines the measured exposure range, population, interactions, production and clearance bounds, toxic thresholds, uncertainty, and strict margin. No arbitrary-dose claim is permitted.", "prohibited_inference": "Enzyme-occupancy saturation cannot construct an unlimited-dose safety theorem.", "required_evidence": [ "supratherapeutic_exposure_data_where_ethical", "toxicokinetic_bounds", "metabolite_and_off_target_bounds", "interaction_and_vulnerable_population_data", "domain_limited_mathematical_certificate" ], "source_ids": [ "NOVA4_WHITEPAPER_CURRENT", "FDA_ICH_S7A", "FDA_ABUSE_POTENTIAL" ], "status": "BLOCKED_NO_DIRECT_EVIDENCE" } ], "mechanism_roles": [ { "assigned_features": [ "NOVA4-FEAT-001", "NOVA4-FEAT-002", "NOVA4-FEAT-005", "NOVA4-FEAT-006", "NOVA4-FEAT-007", "NOVA4-FEAT-008", "NOVA4-FEAT-009", "NOVA4-FEAT-010", "NOVA4-FEAT-011", "NOVA4-FEAT-012" ], "component": "C1", "current_status": "HYPOTHESIS_NO_DIRECT_COMPONENT_DATA", "intended_distribution": "Measured CNS exposure and target engagement without assuming synapse- or region-selective amplification", "intended_target": "Dual human NEP/APN inhibition with endogenous opioid amplification", "required_component_evidence": [ "human_NEP_potency", "human_APN_potency", "proteome_and_metalloprotease_selectivity", "unbound_brain_and_plasma_PK", "CNS_target_engagement", "enkephalin_exposure_response", "cardiovascular_peptide_liability" ] }, { "assigned_features": [ "NOVA4-FEAT-001", "NOVA4-FEAT-003", "NOVA4-FEAT-008", "NOVA4-FEAT-009", "NOVA4-FEAT-011", "NOVA4-FEAT-012" ], "component": "C2", "current_status": "HYPOTHESIS_NO_DIRECT_COMPONENT_DATA", "intended_distribution": "Peripherally restricted by design; no direct central subjective contribution is credited without measured CNS exposure", "intended_target": "Human FAAH inhibition with peripheral analgesic and combination contribution", "required_component_evidence": [ "human_FAAH_potency", "covalent_proteome_selectivity", "active_metabolites", "unbound_brain_to_plasma_ratio", "peripheral_target_engagement", "factorial_C1_interaction" ] }, { "assigned_features": [ "NOVA4-FEAT-001", "NOVA4-FEAT-004", "NOVA4-FEAT-008", "NOVA4-FEAT-009", "NOVA4-FEAT-011", "NOVA4-FEAT-012" ], "component": "C3", "current_status": "HYPOTHESIS_NO_DIRECT_COMPONENT_DATA", "intended_distribution": "Distribution must be measured; the legacy peripheral design does not itself establish a central warmth or bonding effect", "intended_target": "Selective human OTR agonism with analgesic and affective contribution", "required_component_evidence": [ "human_OTR_functional_pharmacology", "V1a_V1b_V2_selectivity", "biased_signaling_characterization", "unbound_tissue_distribution", "hemodynamic_and_endocrine_safety", "factorial_C1_C2_interaction", "context_stratified_social_effects" ] } ], "profile": { "certification_rule": "PHENOTYPE_CERTIFIED iff every NOVA4-FEAT result is PASS under one prespecified protocol set, every evidence hash resolves, all three exact components match the selected combination, and independent clinical pharmacology, biostatistics, abuse-liability, pain, safety, and outcome-measure reviews are satisfied.", "constructive_interpretation": "The requested phenotype is a conjunction of separately measured desired outputs and safety constraints for one exact selected C1/C2/C3 combination. Molecular mechanism is supporting evidence, never a substitute for direct phenotype evidence.", "current_status": "BLOCKED_NO_SELECTED_COMBINATION_OR_DIRECT_PHENOTYPE_DATA", "legacy_request": "Opioid-level analgesia plus lucid, warm, relaxed, affiliative euphoria with full alertness and cognitive clarity, without sedation, respiratory suppression, addiction, dependence, systemic toxicity, or lethal overdose.", "profile_id": "NOVA4-PHENOTYPE-V1" }, "program_state": "PHENOTYPE_SPECIFICATION_COMPLETE_NO_PHENOTYPE_CERTIFIED", "schema_version": "1.0", "source_hashes": { "phenotype_source_snapshot": "3d3779860e20cc34c8cb81e8b3b17594b18ff6adcf5b8c32ae578eb26df466fd", "synthesis_target_registry": "8723be98973193c1569e2cc26e1cd03c22798b25ddab40e159ba269df82f4a15" } }